Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells

被引:66
作者
Riesterer, O
Zingg, D
Hummerjohann, J
Bodis, S
Pruschy, M [1 ]
机构
[1] Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland
关键词
PKB/Akt; VEGF receptor; rapamycin; PTK787/ZK222584; protein degradation;
D O I
10.1038/sj.onc.1207596
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An intact VEGF receptor/PI3K/PKB/Akt signaling cascade protects endothelial cells from apoptotic stress-stimuli and mediates the formation of new blood vessels in pathological conditions such as cancer. Therefore, downregulation of this signaling cascade is of clinical interest for antiangiogenic cancer therapy. In this report, we demonstrate that VEGF controls the protein stability of the serine-threonine kinase PKB/Akt via inhibition of PKB/Akt protein degradation. VEGF deprivation or blockage of the VEGF signal transduction cascade with the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 resulted in a specific decrease of the PKB/Akt protein level and subsequent cellular restimulation with VEGF rescued its stability. Real-time quantitative RTPCR analysis demonstrated that VEGF does not regulate PKB/Akt gene expression. On the other hand, broad range inhibitors of caspases and the proteasome complex prevented VEGF-dependent downregulation of the PKB/Akt protein level indicating that PKB/Akt protein stability is regulated by VEGF-controlled proteolysis. Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. These results demonstrate a novel regulatory mechanism of the activated VEGF receptor/mTOR-signal transduction pathway to control the protein stability of PKB/Akt and survival threshold in endothelial cells.
引用
收藏
页码:4624 / 4635
页数:12
相关论文
共 71 条
[11]  
BROWN LF, 1993, CANCER RES, V53, P4727
[12]  
Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO
[13]  
2-O
[14]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[15]   Dissection of angiogenic signaling in zebrafish using a chemical genetic approach [J].
Chan, J ;
Bayliss, PE ;
Wood, JM ;
Roberts, TM .
CANCER CELL, 2002, 1 (03) :257-267
[16]   Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas [J].
Chaudhry, IH ;
O'Donovan, DG ;
Brenchley, PEC ;
Reid, H ;
Roberts, ISD .
HISTOPATHOLOGY, 2001, 39 (04) :409-415
[17]   Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin [J].
Decker, T ;
Hipp, S ;
Ringshausen, I ;
Bogner, C ;
Oelsner, M ;
Schneller, F ;
Peschel, C .
BLOOD, 2003, 101 (01) :278-285
[18]   Mechanisms and consequences of activation of protein kinase B/Akt [J].
Downward, J .
CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (02) :262-267
[19]  
Eshleman JS, 2002, CANCER RES, V62, P7291
[20]   Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications [J].
Ferrara, N .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :10-14